FDA Drug Shortage Strategy: Heparin Is Test Case For Developing Alternate Sources
This article was originally published in The Pink Sheet Daily
Executive Summary
Science board encourages agency to address broader economic shortage causes.
You may also be interested in...
Drug Shortage Prevention Could Be Funded Through GDUFA
GPhA recommends FDA deploy user fee research money to look at shortage risk assessment and mitigation strategies, while the trade group continues to look for a product to fit its own shortage prediction model.
House Investigation Of Tainted Heparin Could Highlight Need For Import Safety Legislation - Or Not
Energy and Commerce Republicans seek to determine who contaminated heparin supplies in 2008, how they did it, and why FDA has failed to answer those questions as the panel begins oversight of the agency.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.